{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Steroid+Refractory+GVHD&page=2",
    "query": {
      "condition": "Steroid Refractory GVHD",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Steroid+Refractory+GVHD&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T02:12:39.480Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04744116",
      "title": "Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Steroid Refractory Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "Cellular Therapy",
          "type": "OTHER"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "12 Years to 80 Years"
      },
      "enrollment_count": 24,
      "start_date": "2021-02-17",
      "completion_date": "2032-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-05-22T02:12:39.480Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04744116"
    },
    {
      "nct_id": "NCT02841995",
      "title": "A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft vs Host Disease"
      ],
      "interventions": [
        {
          "name": "Belumosudil (KD025)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kadmon, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2016-09-15",
      "completion_date": "2022-05-12",
      "has_results": true,
      "last_update_posted_date": "2023-06-28",
      "last_synced_at": "2026-05-22T02:12:39.480Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Minneapolis, Minnesota • Cincinnati, Ohio + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02841995"
    },
    {
      "nct_id": "NCT02694770",
      "title": "A Study Evaluating the Efficacy and Safety of Neihulizumab vs \"Conventional Treatment\" to Treat Sr-aGvHD",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Neihulizumab Treatment",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Conventional Treatment",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AbGenomics B.V Taiwan Branch",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-07",
      "completion_date": "2018-02",
      "has_results": false,
      "last_update_posted_date": "2016-04-25",
      "last_synced_at": "2026-05-22T02:12:39.480Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Seattle, Washington",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02694770"
    },
    {
      "nct_id": "NCT02086513",
      "title": "Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "LDE225",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2014-04",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2018-03-19",
      "last_synced_at": "2026-05-22T02:12:39.480Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02086513"
    },
    {
      "nct_id": "NCT00032773",
      "title": "Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "pentostatin for injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astex Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 36,
      "start_date": "2002-01-30",
      "completion_date": "2005-11-03",
      "has_results": false,
      "last_update_posted_date": "2024-08-02",
      "last_synced_at": "2026-05-22T02:12:39.480Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00032773"
    },
    {
      "nct_id": "NCT01700036",
      "title": "A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft vs Host Disease"
      ],
      "interventions": [
        {
          "name": "Alpha-1-Antitrypsin (AAT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2013-07",
      "completion_date": "2018-10-26",
      "has_results": true,
      "last_update_posted_date": "2018-11-27",
      "last_synced_at": "2026-05-22T02:12:39.480Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01700036"
    },
    {
      "nct_id": "NCT01453140",
      "title": "In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide and Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Low dose IL-2 with Cytoxan + Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Low dose IL-2, Vidaza, Cytoxan & Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hackensack Meridian Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 3,
      "start_date": "2011-08",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-05-22T02:12:39.480Z",
      "location_count": 1,
      "location_summary": "Hackensack, New Jersey",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01453140"
    },
    {
      "nct_id": "NCT01475162",
      "title": "Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2011-08-08",
      "completion_date": "2018-09-29",
      "has_results": true,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-05-22T02:12:39.480Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01475162"
    },
    {
      "nct_id": "NCT00760981",
      "title": "A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Graft vs Host Disease"
      ],
      "interventions": [
        {
          "name": "Imatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David Miklos",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2008-09",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2020-04-15",
      "last_synced_at": "2026-05-22T02:12:39.480Z",
      "location_count": 2,
      "location_summary": "Stanford, California • Seattle, Washington",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00760981"
    },
    {
      "nct_id": "NCT02340676",
      "title": "A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Graft-versus-host-disease"
      ],
      "interventions": [
        {
          "name": "Extracorporeal Photopheresis (ECP)",
          "type": "PROCEDURE"
        },
        {
          "name": "Interleukin-2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2015-02",
      "completion_date": "2025-09",
      "has_results": true,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-05-22T02:12:39.480Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02340676"
    }
  ]
}